UBS Group AG Purchases 196,015 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)

UBS Group AG lifted its stake in shares of Viking Therapeutics, Inc. (NASDAQ:VKTXFree Report) by 136.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 339,726 shares of the biotechnology company’s stock after acquiring an additional 196,015 shares during the quarter. UBS Group AG owned approximately 0.34% of Viking Therapeutics worth $6,322,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Wetzel Investment Advisors Inc. purchased a new position in shares of Viking Therapeutics during the fourth quarter worth approximately $37,000. Corton Capital Inc. purchased a new position in Viking Therapeutics during the third quarter valued at approximately $133,000. Aigen Investment Management LP purchased a new position in Viking Therapeutics during the third quarter valued at approximately $148,000. Oppenheimer & Co. Inc. raised its stake in Viking Therapeutics by 31.9% in the third quarter. Oppenheimer & Co. Inc. now owns 16,819 shares of the biotechnology company’s stock worth $186,000 after buying an additional 4,068 shares in the last quarter. Finally, JFG Wealth Management LLC purchased a new stake in Viking Therapeutics during the fourth quarter worth $223,000. 76.03% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on VKTX. Raymond James reiterated a “strong-buy” rating on shares of Viking Therapeutics in a research note on Tuesday. Jefferies Financial Group began coverage on shares of Viking Therapeutics in a research report on Thursday, March 7th. They issued a “buy” rating and a $110.00 price objective on the stock. William Blair reaffirmed an “outperform” rating on shares of Viking Therapeutics in a research report on Friday, February 23rd. Maxim Group reaffirmed a “buy” rating and issued a $120.00 price objective on shares of Viking Therapeutics in a research report on Tuesday. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $90.00 price objective on shares of Viking Therapeutics in a research report on Tuesday. One analyst has rated the stock with a sell rating, eight have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $112.38.

Read Our Latest Stock Report on Viking Therapeutics

Insider Buying and Selling

In other Viking Therapeutics news, COO Marianna Mancini sold 281,425 shares of Viking Therapeutics stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $78.66, for a total transaction of $22,136,890.50. Following the completion of the sale, the chief operating officer now directly owns 348,508 shares in the company, valued at approximately $27,413,639.28. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, CFO Greg Zante sold 66,756 shares of the firm’s stock in a transaction dated Friday, May 3rd. The stock was sold at an average price of $74.69, for a total transaction of $4,986,005.64. Following the sale, the chief financial officer now directly owns 174,854 shares of the company’s stock, valued at $13,059,845.26. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, COO Marianna Mancini sold 281,425 shares of the firm’s stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $78.66, for a total value of $22,136,890.50. Following the sale, the chief operating officer now directly owns 348,508 shares in the company, valued at $27,413,639.28. The disclosure for this sale can be found here. 4.70% of the stock is owned by corporate insiders.

Viking Therapeutics Stock Down 6.6 %

VKTX stock opened at $55.01 on Friday. The firm has a 50 day moving average of $70.46 and a 200 day moving average of $46.98. The stock has a market capitalization of $6.07 billion, a PE ratio of -59.15 and a beta of 1.04. Viking Therapeutics, Inc. has a 52 week low of $8.28 and a 52 week high of $99.41.

Viking Therapeutics (NASDAQ:VKTXGet Free Report) last announced its quarterly earnings data on Wednesday, April 24th. The biotechnology company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.01. During the same period last year, the business earned ($0.25) earnings per share. On average, equities research analysts expect that Viking Therapeutics, Inc. will post -1.08 earnings per share for the current year.

Viking Therapeutics Profile

(Free Report)

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.

Featured Articles

Institutional Ownership by Quarter for Viking Therapeutics (NASDAQ:VKTX)

Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.